Voluntary announcement - IND approval by china CDE for mRNA mpox vaccine
Filed with HKEX · · 2 pages · English
Summary by 6ix AI
Ab&B Bio-Tech Co., Ltd. JS has announced the approval of its mRNA mpox vaccine candidate by the China CDE, following prior approval from the U.S. FDA. This marks the first mRNA mpox vaccine candidate to receive IND approval from both regulatory bodies. The company emphasizes the vaccine's superior immunogenicity compared to existing options, particularly for immunocompromised individuals.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Ab&B Bio-Tech Co., Ltd. JS on 6ix
Later from Ab&B Bio-Tech Co., Ltd. JS
- (I) resignation of executive director and chief financial officer (ii) nomination of executive directors (iii) appointment of chief financial officer (iv) change of members of board committees (v) appointment of board secretary and joint company secretary (vi) waiver from strict compliance with rules 3.28 and 8.17 of the listing rules (vii) change of authorized representative and (viii) continued suspension of trading
- List of directors and their roles and functions
- Quarterly update on resumption progress and continued suspension of trading
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Resignation of non-executive director; and (2) continued suspension of trading
Follow Ab&B Bio-Tech Co., Ltd. JS into a list and get an email when it puts out news.
Follow Ab&B Bio-Tech Co., Ltd. JS